As of 2:30 PM on the 16th, Pamicell is trading at 15,850 KRW, down 11.7% from the previous day. This represents a 21.92% decrease compared to September 15. Pamicell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.
Today, foreigners have a net purchase of 48,259 shares of Pamicell, while institutions have a net sale of 7,000 shares, according to provisional data. Over the past five days, individual investors have net sold 95,884 shares, while foreigners and institutions have net bought 72,374 shares and 26,090 shares, respectively.


※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

